Linked Life Data

7740337

Source:http://linkedlifedata.com/resource/pubmed/id/7740337

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2 Suppl 5
pubmed:dateCreated
1995-6-5
pubmed:abstractText
Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Médicament, Paris, France) has been formulated as a liquid-filled, soft gelatin capsule. Pharmacokinetic studies of this agent indicate that it has a large volume of distribution, a long terminal half-life, and a high clearance rate. The pharmacokinetics of vinorelbine are similar whether the drug is administered orally or intravenously. Oral vinorelbine has a low bioavailability, which may be due to a high first-pass effect. Preliminary results from two multicenter phase II trials of oral vinorelbine in patients with advanced breast cancer are presented. In one study of 98 advanced breast cancer patients aged 65 years and older with limited prior therapy, the response rate of oral vinorelbine was 24% (complete response, 5%; partial response, 19%). In a study of 131 heavily pretreated patients with advanced breast cancer, the response rate of oral vinorelbine was 11% (complete response, 0%; partial response, 11%). In both studies, oral vinorelbine was generally well tolerated. As with intravenous administration, neutropenia is common and neuropathy is infrequent. In contrast to intravenous administration, nausea, vomiting, and diarrhea are common. Based on these preliminary results, further clinical investigation of oral vinorelbine is warranted.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0093-7754
pubmed:author
pubmed:issnType
Print
pubmed:volume
22
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
72-8; discussion 78-9
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.
pubmed:affiliation
Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA.
pubmed:publicationType
Journal Article, Review